Treatment of chronic migraine headache with onabotulinumtoxinA

Research output: Contribution to journalArticle

Abstract

Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.

Original languageEnglish (US)
Pages (from-to)336-338
Number of pages3
JournalCurrent Pain and Headache Reports
Volume15
Issue number5
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Headache Disorders
Migraine Disorders
Trigger Points
Therapeutics
onabotulinumtoxinA
Injections

Keywords

  • Botulinum toxin A
  • Injection
  • Migraine
  • Migraine trigger
  • MTrP
  • Myofascial trigger points
  • Onabotulinumtoxin
  • Onabotulinumtoxina
  • PREEMPT 1
  • PREEMPT 2
  • PREEMPT trials
  • Referred pain
  • Trigger points

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Treatment of chronic migraine headache with onabotulinumtoxinA. / Gerwin, Robert.

In: Current Pain and Headache Reports, Vol. 15, No. 5, 01.10.2011, p. 336-338.

Research output: Contribution to journalArticle

@article{70df75bdf4e14e8686bb4c10c372b55e,
title = "Treatment of chronic migraine headache with onabotulinumtoxinA",
abstract = "Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.",
keywords = "Botulinum toxin A, Injection, Migraine, Migraine trigger, MTrP, Myofascial trigger points, Onabotulinumtoxin, Onabotulinumtoxina, PREEMPT 1, PREEMPT 2, PREEMPT trials, Referred pain, Trigger points",
author = "Robert Gerwin",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s11916-011-0202-6",
language = "English (US)",
volume = "15",
pages = "336--338",
journal = "Current Pain and Headache Reports",
issn = "1531-3433",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of chronic migraine headache with onabotulinumtoxinA

AU - Gerwin, Robert

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.

AB - Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.

KW - Botulinum toxin A

KW - Injection

KW - Migraine

KW - Migraine trigger

KW - MTrP

KW - Myofascial trigger points

KW - Onabotulinumtoxin

KW - Onabotulinumtoxina

KW - PREEMPT 1

KW - PREEMPT 2

KW - PREEMPT trials

KW - Referred pain

KW - Trigger points

UR - http://www.scopus.com/inward/record.url?scp=80755138425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755138425&partnerID=8YFLogxK

U2 - 10.1007/s11916-011-0202-6

DO - 10.1007/s11916-011-0202-6

M3 - Article

C2 - 21547527

AN - SCOPUS:80755138425

VL - 15

SP - 336

EP - 338

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

SN - 1531-3433

IS - 5

ER -